DMG Mori has fixed the price on the overseas share sale it announced last week: ¥3,349 per share, for the offering to investors in Europe and Asia excluding the US and Canada. The board settled the figure on August 12, and the machine-tool maker filed a second amended extraordinary report with the Kanto Local Finance Bureau on August 13 to lock in the terms.
The Companies Act paid-in amount, a separate figure used to calculate the resulting capital increase, comes to ¥3,202.56 a share. Together the new shares carry a total issue value of ¥48.0bn. After roughly ¥300mn in issuance costs, DMG Mori expects to net ¥47.7bn.
Until Wednesday, the offer price itself was tied to a formula: 90 to 100 percent of the Tokyo Stock Exchange closing price on the pricing date. The Companies Act paid-in amount, by contrast, was listed only as undetermined, to be fixed the same day through a comparable bookbuilding process, without that specific percentage range attached to it.
DMG Mori has set out five uses for the ¥47.7bn:
| Use of proceeds | Amount | Spending deadline |
|---|---|---|
| Nagaoka plant capacity expansion (combines two existing factories) | ¥15.0bn | Operational from January 2027 |
| Poland factory casting-parts insourcing | ¥14.0bn | By the fiscal year ending December 2028 |
| Chicago R&D center and customer showroom | ¥6.0bn | By the first half of 2027 |
| Key-component in-house production capacity | ¥2.7bn | By the fiscal year ending December 2028 |
| M&A standby fund | ¥10.0bn | No fixed deadline; unspent balance goes to debt repayment after December 2028 |
The Nagaoka plant, which combines two existing factories into a single site, is meant to add production capacity and is due to start operating in January 2027. The Poland expansion is aimed at making cast parts in-house, which the company says will harden its supply chain and cut carbon emissions; that spending runs through the fiscal year ending December 2028, the same deadline attached to the key-component production line. The Chicago center covers both R&D work and a customer-facing showroom meant to widen DMG Mori's reach in the North American market.
The ¥2.7bn earmarked for in-house key-component capacity is lower than the ¥3.2bn DMG Mori had pencilled in before this week's correction; the filing does not explain the reduction.
The ¥10bn M&A reserve is not tied to any named target. DMG Mori says it continuously reviews consolidation opportunities with other machine-tool makers and technology or software businesses it does not currently own, but nothing specific has been decided. Any of the ¥47.7bn left unspent by the end of December 2028 will go toward repaying interest-bearing debt instead, and until it is deployed the company says the money will sit in its bank accounts.
The same day, DMG Mori filed a separate amendment noting that the corrected extraordinary report now serves as a reference document for its existing ¥50bn corporate-bond shelf registration, which still has ¥33bn of unused capacity through January 2027. That filing does not change the bond program's terms.